Organization | Fundacion Instituto Valenciano de Oncologia

Fundacion Instituto Valenciano de Oncologia Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2015

NCT02684318

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

FIVO | Fundacion Instituto Valenciano de Oncologia | Instituto Valenciano de Oncología | Poveda, Andrés, M.D.

Active Ingredients

Drugs in Phase 2 Trials (9)

abemaciclib (verzenio) (1 trial)

cabozantinib (cometriq) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

letrozole (femara) (1 trial)

lurbinectedin (Zepzelca) (1 trial)

olaparib (lynparza) (2 trials)

paclitaxel (taxol) (1 trial)

ribociclib (kisqali) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Endometrial Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 9